RECRUITING

AngelMed Guardian® System PMA Post Approval Study

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.

Official Title

AngelMed Guardian® System PMA Post Approval Study

Quick Facts

Study Start:2022-09-07

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05412927

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* 1. Subject has at least one of the following conditions: 1. Diabetes (Type I or Type II) 2. Compromised renal function (Cr \> 1.2 mg/dl or creatinine clearance less than 50) 3. TIMI Risk Score of at least 3 2. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation. 3. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure. 4. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI. 5. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following: 1. Post-menopause or amenorrhoeic during the past year 2. Surgical sterilization 3. Use of effective contraceptive method	* 1. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc. 2. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location. 3. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion. 4. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest. 5. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB. 7. Subject has left ventricular hypertrophy evidenced by EKG criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line. 9. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years. 10. There is evidence of unresolved infection (fever \> 38o C and/or leukocytosis \> 15,000). 11. Subject has history of bleeding disorders or severe coagulopathy (platelets \< 100,000 plts/ml; APTT or PT \> 1.3 x reference range). 12. Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months. 13. Subject has a potentially fatal disease, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy, which may lead to inadequate compliance to the protocol or confusing data interpretation. 14. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures. 15. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor. 16. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is contraindicated for at least 6 months. 18. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Inclusion Criteria

Exclusion Criteria

* 1. Subject has at least one of the following conditions:
1. Diabetes (Type I or Type II)
2. Compromised renal function (Cr \> 1.2 mg/dl or creatinine clearance less than 50)
3. TIMI Risk Score of at least 3
2. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation.
3. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure.
4. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI.
5. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:
1. Post-menopause or amenorrhoeic during the past year
2. Surgical sterilization
3. Use of effective contraceptive method

* 1. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc.
2. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location.
3. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion.
4. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest.
5. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB.
7. Subject has left ventricular hypertrophy evidenced by EKG criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line.
9. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years.
10. There is evidence of unresolved infection (fever \> 38o C and/or leukocytosis \> 15,000).
11. Subject has history of bleeding disorders or severe coagulopathy (platelets \< 100,000 plts/ml; APTT or PT \> 1.3 x reference range).
12. Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months.
13. Subject has a potentially fatal disease, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy, which may lead to inadequate compliance to the protocol or confusing data interpretation.
14. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures.
15. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor.
16. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is contraindicated for at least 6 months.
18. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Contacts and Locations

Study Contact

Jacqueline Finley, BS

CONTACT

732.542.5551

jfinley@avertix.com

Sasha John, PhD

CONTACT

6466444661

sjohn@avertix.com

Principal Investigator

David Keenan

STUDY_DIRECTOR

Angel Medical Systems Inc.

Sasha John, PhD

STUDY_DIRECTOR

Angel Medical Systems Inc.

Haroon Faraz, MD

PRINCIPAL_INVESTIGATOR

Hackensack-Meridian Health Care System

Study Locations (Sites)

Southwest Cardiovascular Associates

Mesa, Arizona, 85208

United States

East Los Angeles Cardiology

Los Angeles, California, 90033

United States

Orange County Heart and Research Institute

Orange, California, 92868

United States

Clermont Ambulatory Surgical Center

Clermont, Florida, 34711

United States

Florida Heart Rhythm Specialists

Fort Lauderdale, Florida, 33308

United States

Institute for Cardiovascular Research Studies, Inc.

Miami, Florida, 33176

United States

LEJ Medical, LLC

New Smyrna Beach, Florida, 32168

United States

Northside Hospital Cardiovascular Institute

Atlanta, Georgia, 30342

United States

Cardiovascular Associate Research

Covington, Louisiana, 70433

United States

Heart Clinic of Hammond

Hammond, Louisiana, 70403

United States

North Shore Heart and Vascular

Mandeville, Louisiana, 70448

United States

Corewell Health

Grand Rapids, Michigan, 49503

United States

South Oklahoma Heart Research

Oklahoma City, Oklahoma, 73135

United States

Texan Cardiovascular Institute

El Paso, Texas, 79915

United States

Medical City Hospital Forth Worth

Fort Worth, Texas, 76104

United States

Collaborators and Investigators

Sponsor: Angel Medical Systems

David Keenan, STUDY_DIRECTOR, Angel Medical Systems Inc.
Sasha John, PhD, STUDY_DIRECTOR, Angel Medical Systems Inc.
Haroon Faraz, MD, PRINCIPAL_INVESTIGATOR, Hackensack-Meridian Health Care System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-07

Study Completion Date2026-12

Study Record Updates

Study Start Date2022-09-07

Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

Acute Coronary Syndrome